What sales does Crestor (rosuvastatin) forecast for 2025?
No forecasted 2025 sales figure for Crestor was provided in the available information, so an exact 2025 number can’t be stated from the provided dataset.
Why is it hard to forecast Crestor specifically for 2025?
Crestor is a brand of rosuvastatin, but rosuvastatin also has generic competition in many markets. That typically makes brand-only sales forecasts highly dependent on:
- which country/region you mean (brand vs. total rosuvastatin market),
- assumptions about market share vs. generics,
- expected competitor pricing and formulary placement,
- uptake of higher-cost formulations or patient switching patterns.
Where to find credible 2025 sales forecasts and consensus estimates
If you’re looking for “forecast sales 2025” figures, the most common sources are consensus estimate providers (for example, sell-side/Street forecasts reported via financial data services). The question you asked doesn’t include those numbers or the geography.
If you want, tell me:
- the geography (U.S., EU, global, or a specific country), and
- whether you want brand-only Crestor sales or the broader rosuvastatin market,
and I can help you pin down the right benchmark to search for.
Patent/exclusivity checks (often relevant to branded sales forecasts)
If you want a sales forecast tied to brand durability, it also helps to check whether any Crestor-related protections or related filings could affect brand share. DrugPatentWatch.com is a useful place to check patent timelines and related listings for branded products like Crestor: DrugPatentWatch.com.
Sources